Objective: To evaluate the effectiveness in diagnosing mammographically and sonographically occult breast lesions by using magnetic resonance imaging (MRI) guided vacuum-assisted breast biopsy in patients who presented to a community-based hospital with a newly established breast MRI program. Methods: The records of 142 consecutive patients, median age of 55 years, who had undergone MRI-guided biopsy at our institution between July 2006 and July 2007 were reviewed. From these patients, 197 mammographically and sonographically occult lesions were biopsied at the time of discovery. The pathology was then reviewed and correlated with the MRI findings. Results: Cancer was present and subsequently discovered in 8% of the previously occult lesions (16/197) or 11% of the women studied (16/ 142). Of the cancerous lesions, 56% were invasive carcinomas (9/16) and 44% were ductal carcinomas in situ (7/16). Fourteen percent of the discovered lesions (28/197) were defined as high risk and included atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, and radial scar. In total, occult cancerous and high-risk lesions were discovered in 22% of the found lesions (44/197) or 31% of the women who underwent MRI-guided biopsy (44/142). Conclusions: This study demonstrated that detection of cancerous and high-risk lesions can be significantly increased when an MRI-guided biopsy program is introduced at a community-based hospital. We believe that as radiologists gain confidence in imaging and histologic correlation, community-based hospitals can achieve similar rates of occult lesion diagnosis as those found in data emerging from academic institutions. Conclusions: Cette étude a démontré que l'établissement d'un programme de biopsie guidée par IRM dans un hôpital communautaire peut considérablement faciliter la détection de lésions cancéreuses et à haut risque. Nous croyons qu'au fur et à mesure que les radiologistes prendront de l'assurance en imagerie et en corrélation histologique, les hôpitaux communautaires pourront parvenir à des résultats en diagnostic de lésions occultes semblables à ceux exprimés dans les données provenant des établissements universitaires.
Introduction
The need for accurate early detection and diagnosis of breast cancer has led to an increased demand for breast magnetic resonance imaging (MRI) and percutaneous biopsy options. Ovel et al [1] and Kriege et al [2] suggested that the overall discriminating ability of MRI in breast cancer is significantly better than mammography, and current estimates of occult cancers subsequently discovered by using MRI-guided breast biopsies are upward of 30% [1, 2] . The aim of our study was to investigate, in a community setting, the role of MRI as a more sensitive imaging modality to detect otherwise occult breast lesions compared with traditional mammography or ultrasonography.
Breast MRI is an important adjunct to the conventional imaging modalities in the detection and assessment of primary and recurrent breast cancers that remain mammographically, sonographically, and clinically occult [3e6] . After a diagnosis of breast cancer, MRI may provide a more accurate assessment of the extent of disease than conventional modalities and physical examination [7, 8] . MRI has been successfully used to evaluate contralateral and ipsilateral breasts recently diagnosed with cancer to identify multifocal or multicentric disease [9, 10] . Breast MRI has also proven successful in evaluating post-lumpectomy and post-implant breasts, and in screening women with high-risk factors, such as a genetic predisposition to disease, a family history of cancer, and dense breast composition. In addition, breast MRI has been useful in the evaluation of patients with isolated axillary metastasis suspect for occult primary breast cancer [11] .
No longer is MRI-guided breast biopsy limited to large academic institutions. The decreasing costs of MRI-guided vacuum-assisted biopsy devices, combined with the greater availability of high-quality breast MRI and well-trained technicians has enabled many community hospitals and imaging centers to offer MRI-guided core biopsy of the breast.
After the introduction of a breast MRI program to our hospital, we examined MRI-guided biopsy specimens of those lesions found to be mammographically and sonographically occult. In this article, we present a retrospective review of our initial experiences and outcomes in a community-based hospital.
Materials and Methods
Between July 2006 and July 2007, Morristown Memorial Hospital, Morristown, NJ, performed approximately 1,200 breast MRI studies and provided MRI-guided needle localization and biopsy for suspicious lesions. The pathologies of the first 142 consecutive patients who underwent MRIguided vacuum-assisted core biopsy during the designated study interval were retrospectively reviewed. These initial 142 MRI-guided biopsies were investigated so that we might assess the utility of MRI breast imaging and correlate our findings with future studies as our program developed. This retrospective study was approved by the institutional review board of Atlantic Health, Morristown Memorial Hospital.
Patients were selected for screening or diagnostic MRI based on clinical assessment and, in some cases, clinical assessment and the American Cancer Society guidelines for breast screening [12] . Multiple selection criteria were used to determine a patient's inclusion: newly diagnosed breast cancer, BRCA 1 or 2 mutations, personal history or a firstdegree relative with a history of breast cancer, radiation to the chest between the ages of 10 and 30 years, heterogeneous or extremely dense breast tissue on mammography, a lifetime cancer risk of 15%e20%, an indeterminate physical examination, histologic findings of atypical lobular hyperplasia (ALH), atypical ductal hyperplasia (ADH), or lobular carcinoma in situ (LCIS).
All 142 women, median age of 55 years, had lesions discovered by MRI, with negative mammograms (BI-RADS 1 or 2), as indicated by the American College of Radiology Breast Imaging and Reporting Data System (BI-RADS), 4th ed, Reston, VA, and negative ultrasounds at least 3 months before biopsy. Once identified with MRI, the lesion morphology was described and correlated with the approximate size and degree of enhancement, and the previously occult lesions were subjected to additional mammography and targeted ultrasound as a ''second look.'' Those lesions initially detected by MRI and subsequently revealed by ''second look'' studies were excluded, as our study focused solely on lesions occult to these techniques. If the additional imaging and ultrasound were inconclusive (the lesion was mammographically and sonographically occult), then a recommendation for MRI biopsy was issued. Lesions not visualized with ''second look'' techniques underwent MRIguided biopsy performed by 1 of 3 breast fellowship-trained, board-certified radiologists.
Within 6 months of their initial MRI-guided biopsy, all patients were followed up at our institution with another diagnostic breast MRI to document the stability of the biopsied lesion. The histopathology of each specimen was then reviewed. Only 1 patient had interval growth at 6 months after the MRI-guided core biopsy, which may have been because of sampling error, and the decision was made to remove the entire region with MRI-guided localization. The lesion subsequently revealed ductal carcinoma in situ (DCIS). Of the remaining 141 patients, no new diagnoses of cancer have been reported since the writing of this article.
The decision to biopsy a specific lesion, by using MRIguided vacuum assistance, was multifactorial. Radiologists' recommendations for biopsy focused on lesion morphology, degree of enhancement, and lesion size. Physician-referred requests for biopsy were accepted based on the physician's assessment of clinical risk. Clinical risk factors included the following: family history; menopausal status; mammographic parenchymal density; and personal breast cancer history, subdivided into ipsilateral and contralateral breast cancer; and a recent (within 1 year) or remote history of cancer.
MRI and Biopsy Techniques
One hundred of the studied patients were scanned by using a 1.5-T GE Signa Excite system (GE Medical Systems, Waukesha, WI). The remaining 42 patients were scanned by using a 1.5-T Philips Intera system (Philips Medical Systems, Best, The Netherlands). Two different breast MRI coils were used. The 7CH InVivo Breast MRI coil (InVivo Corporation, Orlando, FL) was used on both the Philips MRI and GE MRI systems in our hospital practice. An 8CH-USA Coil (GE Medical) was used at our outpatient facility on a 1.5T GE Signa Excite MRI (GE Medical).
All acquisitions were performed in an axial plane, with imaging bilaterally. The protocol included two-dimensional, multislice, turbo spin-echo based T1-and T2-weighted acquisitions. Planning of these acquisitions consisted of thirty 5-mm-thick slices (gap, 0.5 mm), with a field of view of 30 cm. An acquisition matrix of 512 Â 384 was used. The repetition times and echo times were 609 ms and 7 ms for a T1-weighted sequence and 2600 ms and 11.5 ms for a T2-weighted sequence, respectively.
Three-dimensional contrast-enhanced dynamic scans were planned immediately after the two-dimensional scans. Thirty milliliters of gadodiamide intravenous contrast (Omniscan; Amersham Health, Oslo, Norway) were administered, acquiring 7 time points, with the first point acquired before contrast administration, and used as a mark. The dynamic imaging sequence was T1 weighted, with active fat suppression. The field of view was similar to the preceding two-dimensional acquisitions, but the slice thickness was reduced to 2.5 mm, with 80 slices planned axially, which yielded a repetition time and echo time of 11 ms and 5 ms, respectively. An acquisition matrix yielded a temporal resolution of less than 1 minute.
The MRI-guided core needle biopsies were performed by using a 7CH InVivo biopsy breast array coil (InVivo), with a biopsy apparatus, and the SenoRx EnCor vacuum-assisted 10-gauge MRI biopsy device (SenoRx Inc., Aliso Viejo, CA). The MRI protocol was similar to that for diagnostic imaging but lacked the two-dimensional T2-weighted and isotropic acquisition. T1-weighted images were obtained in both the axial and sagittal planes, followed by a threedimensional contrast dynamic scan. Each lesion was identified and biopsied by using these images, and a clip was placed for follow-up localization if needed. Postbiopsy mammograms were performed to guide any subsequent surgical procedures and to ensure proper clip visualization.
Diagnostic MR images were reviewed and analysed on a DynaCAD workstation (InVivo). The analysis was done in accordance with the American College of Radiology guidelines. All studies were reviewed in conjunction with the patient's clinical history, as well as current and available sonograms and mammograms.
Results
Histopathologic examination of 197 biopsied lesions from 142 patients was correlated with the respective MRI findings. Lesion sizes ranged from a small focus of 3 mm to enhancing areas of 40 mm. The smallest cancer localized, an invasive ductal carcinoma, was 4 mm. The largest cancer localized, an infiltrating lobular carcinoma, was 20 mm.
Sixteen pathologic specimens, discovered with MRI and biopsied under MRI guidance, returned with a result positive for cancer, giving 11% of the studied women (16/142) a new diagnosis of breast cancer. The 16 positive pathologies accounted for 8% of the total 197 lesions biopsied. Fifty-six percent of these new cancers (9/16) proved to be invasive carcinomas, with the remaining 44% identified as DCIS (7/16) (Figure 1 ). Of the newly discovered lesions, 4.5% were invasive carcinomas (9/197), whereas 3.5% were DCIS (7/197) . Invasive carcinoma was determined to be in 6% of the women (9/142). DCIS existed in 4.9% of the women (7/142).
High-risk lesions, including ADH, ALH, and LCIS, accounted for 14% of the pathologies (28/197) and 20% of the women studied (28/142) (Figure 2 ). Benign lesions accounted for 78% of the biopsied specimens (153/197). In total, cancer plus high-risk lesions accounted for 22% of the newly Table 1) .
Discussion
Breast MRI has provided an exceptional level of sensitivity to detecting breast cancers of smaller sizes and earlier stages. In 2004, Kriege et al [2] reported the sensitivity of MRI for detecting invasive breast cancer to be 79.5% compared with 17.9% and 33.3% sensitivities for clinical breast examination and mammography, respectively. Despite high sensitivity, breast MRI continues to demonstrate high rates of false positives and varied levels of specificity, calling to question its reliability. However, the incorporation of percutaneous MRIguided core biopsy has provided a fast, minimally invasive way to obtain tissue from lesions only visualized by using MRI. MRI-guided biopsies make it easier to justify wider use of breast MRI by decreasing the need for surgical intervention for lesions that have a high likelihood of being benign, confirming a suspected diagnosis, and directing the patient and clinician towards the proper treatment regimens.
As MRI-guided vacuum-assisted core biopsy becomes more prevalent in the community, there are still many issues related to its uses that must be standardized, including patient-selection criteria, variation in scanning techniques and equipment, radiologist experience, and innate difficulties related to MRI-guided procedures, such as slice thickness, fat saturation, and echo times [13] . Failure to collectively resolve such issues may cause higher rates of false-positive diagnoses and altered outcomes. Moreover, there can be difficulties with MRI-guided biopsies, such as lesions with visibility affected by rapid washout and lesions that may be altered by compression or displaced by lidocaine insertion. In these instances, the radiologist may not be able to obtain the proper amounts of tissue and ensure accuracy.
In our retrospective study, breast MRI-guided core biopsy found occult cancer in 11% of women (16/142 ) and 8% of the lesions biopsied (16/197) . These lesions were not demonstrated on mammography or on ultrasound and would have otherwise gone undetected and untreated at their current stage. Of the cancers detected, approximately half of the lesions were DCIS and half were invasive carcinoma. An additional 20% of women had ADH, ALH, or LCIS (28/ 142). From histopathology of the biopsied specimen, combined rates of cancers and high-risk lesions were discovered in 22% of the lesions localized (44/197), which affected 31% of the women (44/142). Thirty-one percent of our patients were found to have an occult cancer or high-risk lesion. This value approximates the 1995 study by Orel et al [1] , who, by using MRI, detected occult cancers or high-risk lesions in 34% of their studied population. Additional studies by Liberman et al [5, 14] , found occult cancers and high-risk lesions in 25% and 27% of their patients.
Our practice has trended towards detection of high-risk lesions rather than invasive cancer or DCIS. We speculate that this may be related to 2 issues. First, because of the recent introduction and novelty of our breast MRI program, our clinicians have been more reluctant to observe lesions with serial MRI and have been more apt to order MRI-guided biopsies to obtain tissue diagnoses. This may have urged biopsies on smaller lesions that would have otherwise been followed up, thus increasing the occurrence of falsely positive findings. Second, our breast center is staffed with fellowship-trained breast-imaging radiologists who perform all of our own ''second look'' ultrasounds after breast MRI. The high level of operator skill may have led to a greater rate of cancer discovery with the ''second look'' ultrasound and the subsequent exclusion of lesions from the study.
Our experience with MRI of the breast supports literature findings that MRI is a valuable tool in the early detection of cancer and high-risk lesions [15e17] . We sought to evaluate the sensitivity and specificity of MRI-guided biopsy in diagnosing cancerous and high-risk lesions by initiating a retrospective study of 142 women who underwent this procedure for lesions that were not demonstrated on mammography or ultrasound. We conclude that breast MRIguided core biopsy is an important and relevant cancer detection tool that can and should be applied to community hospitals and outpatient facilities.
